Navigation Links
Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
Date:12/10/2013

NEW ORLEANS, Dec. 10, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013. There were seven presentations of clinical data, of which five were oral presentations, including one "Best of ASH" presentation on Waldenstrom's macroglobulinemia (WM). In total, 33 additional pre-clinical and non-clinical presentations provided new discoveries using ibrutinib; seven of these were oral presentations. The presentations further elucidated the mechanism of action of ibrutinib and its effect in the tumor microenvironment and provided data on quality of life changes. Results covered various B-cell malignancies: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), WM, and non-Hodgkin lymphoma (NHL).

"The breadth of data presented at ASH this year demonstrates the scientific community's interest in ibrutinib and builds on the clinical responses seen with ibrutinib as a backbone of combination therapy and as a single agent in multiple B-cell malignancies," said Jesse McGreivy, M.D., Chief Medical Officer, Pharmacyclics. "This year's data explain ibrutinib's effect on the quality of life for patients and build on impressive efficacy and safety results, independent of cytogenetic risk factors. We also now have long-term follow-up in CLL, which suggests continuation of the efficacy and a decrease in overall and severe adverse events."

Clinical Trial Presentation Highlights

Chronic Lymphocytic Leukemia

-POSTER PRESENTATION- Abstract #4163:
The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibruti
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. WuXi PharmaTech to Partner with Pharmacyclics
2. Pharmacyclics Reports Third Quarter 2013 Results
3. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
4. Pharmacyclics Reports Second Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
6. Pharmacyclics Reports First Quarter 2013 Results
7. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
8. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
9. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
10. Pharmacyclics, Inc. Prices Public Offering of Common Stock
11. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... necessary to plan or evaluate anticoagulant therapy, ... hyperhomocystinemia, elevated factor VIII levels, dysfibrinogenemia, factor ... and to assess acquired conditions, such as ... others. Prothrombin levels are also monitored along ...
... has enabled more and more laboratory testing to occur ... is hardly threatened with extinction. National volume data suggest ... before, and the huge range of their capabilities, gold ... of tests assures them an abiding and pivotal position ...
Cached Medicine Technology:Prothrombin Time Comes in Small (CLIA-Waived) Packages 2Prothrombin Time Comes in Small (CLIA-Waived) Packages 3When Volume Matters, Immunoassay Systems Deliver 2When Volume Matters, Immunoassay Systems Deliver 3
(Date:4/18/2014)... 2014) -- A group of scientists from the ... Sanders-Brown Center on Aging has found interesting new ... function in Parkinson,s disease (PD). , Published ... study, which assessed cognitive function in depressed and ... replacement therapy commonly used to treat motor symptoms ...
(Date:4/18/2014)... memories? How did it make you feel? According to ... experience, such as how sad you were or how ... when you can,t stop thinking about it. , ... context of the memories, rather than how you felt, ... the negative effects of these memories, a new study ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... CHAMPAIGN, Ill. One of the most popular vaccine ... choice. And doctors may be overlooking some cost factors ... actually a more expensive option, according to a new ... of vaccines to administer can be driven by numerous ... study and a professor of computer science and of ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... , MONDAY, May 14 (HealthDay News) -- In a ... people with chronic obstructive pulmonary disease (COPD) were more ... tools. "The comprehensive care management program was associated ... Fan, of the Veterans Affairs Puget Sound Health Care ...
... By Kathleen Doheny HealthDay Reporter , ... help relieve muscle tightness, called spasticity, and pain in ... "Spasticity is a major problem [in multiple sclerosis]," ... University of California, San Diego Multiple Sclerosis Center. "People ...
... guys do finish last at least when it comes to ... at San Antonio that answers the question of why women ... of marketing at The University of Texas at San Antonio ... influence women,s perceptions of men as potential fathers. "Previous ...
... A drug that has been shown to prevent HIV ... with behavioral approaches if the U.S. health care establishment is ... to the American Psychological Association. "Exclusive reliance on a ... actually result in a worse outcome if those at risk ...
... HealthDay Reporter , MONDAY, May 14 (HealthDay ... room after accidentally swallowing coin-sized batteries found in many ... new research reveals. Serious complications -- including fatalities ... items ranging from remote-control devices to children,s toys, get ...
... By Randy Dotinga HealthDay Reporter , THURSDAY, May ... on Thursday endorsed the use of the drug Truvada as ... at high risk of contracting the AIDS-causing virus. In ... new weapon in the fight against AIDS, the FDA advisers ...
Cached Medicine News:Health News:'Self-Managing' COPD Might Pose Risks, Study Suggests 2Health News:'Self-Managing' COPD Might Pose Risks, Study Suggests 3Health News:'Self-Managing' COPD Might Pose Risks, Study Suggests 4Health News:Pot Might Help Ease Multiple Sclerosis Symptoms 2Health News:Pot Might Help Ease Multiple Sclerosis Symptoms 3Health News:UTSA study finds ovulating women perceive sexy cads as good dads 2Health News:HIV prevention measures must include behavioral strategies to work, says APA 2Health News:'Button' Batteries Sending More Kids to ER: Study 2Health News:'Button' Batteries Sending More Kids to ER: Study 3Health News:FDA Advisers Back Pill to Help Prevent HIV Infection 2Health News:FDA Advisers Back Pill to Help Prevent HIV Infection 3
Engineered for high volume surgical efficiencies, the Bausch & Lomb Hansatome Microkeratome, a corneal resection instrument, features an automated pivoting motion that provides smooth, resistance-fre...
... provide comprehensive neurological monitoring in the ... to accurately access your patients neurological ... years experience, and a long history ... monitoring systems have a proven record ...
... Alpha 5 is Aloka's latest advance ... operating room. Aloka's ProSound technology transmits ... information in a pure sound field., ... large-scale integration of the electronic circuit ...
Inquire...
Medicine Products: